Moody Aldrich Partners LLC Lowers Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Moody Aldrich Partners LLC trimmed its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 1.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 48,961 shares of the biotechnology company’s stock after selling 918 shares during the period. Moody Aldrich Partners LLC’s holdings in Arrowhead Pharmaceuticals were worth $948,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the stock. Fifth Third Bancorp lifted its stake in Arrowhead Pharmaceuticals by 42.5% in the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 354 shares during the last quarter. Headlands Technologies LLC grew its position in Arrowhead Pharmaceuticals by 7,696.8% during the first quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock worth $69,000 after buying an additional 2,386 shares during the period. Meeder Asset Management Inc. increased its stake in Arrowhead Pharmaceuticals by 4,629.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 3,333 shares in the last quarter. nVerses Capital LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at $96,000. Finally, Quarry LP raised its stake in Arrowhead Pharmaceuticals by 54.5% in the 2nd quarter. Quarry LP now owns 8,500 shares of the biotechnology company’s stock valued at $221,000 after purchasing an additional 3,000 shares during the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Trading Up 1.8 %

Arrowhead Pharmaceuticals stock traded up $0.35 during trading hours on Thursday, reaching $20.27. 112,057 shares of the company were exchanged, compared to its average volume of 1,210,343. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -4.69 and a beta of 0.95. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $17.05 and a 12 month high of $39.83. The stock has a 50-day moving average of $21.20 and a 200 day moving average of $23.80.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.80). During the same period in the prior year, the company posted ($0.96) earnings per share. The firm’s revenue for the quarter was down 100.0% compared to the same quarter last year. As a group, research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -4.31 EPS for the current year.

Analyst Upgrades and Downgrades

ARWR has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, October 11th. Piper Sandler reaffirmed an “overweight” rating and set a $62.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, October 8th. B. Riley reiterated a “buy” rating and set a $55.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 12th. Chardan Capital reiterated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, July 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $45.33.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.